Aprea Therapeutics, Inc.
APRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 157.6% | – | – | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | -523.2% | 98.8% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -951.5% | -2,448.4% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -862.4% | -2,449.6% | – | – |
| EPS Diluted | -2.35 | -3.95 | -1,359.79 | -34.88 |
| % Growth | 40.5% | 99.7% | -3,798.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |